JP2016519091A5 - - Google Patents

Download PDF

Info

Publication number
JP2016519091A5
JP2016519091A5 JP2016503776A JP2016503776A JP2016519091A5 JP 2016519091 A5 JP2016519091 A5 JP 2016519091A5 JP 2016503776 A JP2016503776 A JP 2016503776A JP 2016503776 A JP2016503776 A JP 2016503776A JP 2016519091 A5 JP2016519091 A5 JP 2016519091A5
Authority
JP
Japan
Prior art keywords
phenyl
piperidin
quinoline
chloro
diethylamino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016503776A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016519091A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IL2014/050273 external-priority patent/WO2014147611A1/en
Publication of JP2016519091A publication Critical patent/JP2016519091A/ja
Publication of JP2016519091A5 publication Critical patent/JP2016519091A5/ja
Pending legal-status Critical Current

Links

JP2016503776A 2013-03-18 2014-03-13 新規抗がん剤としてのキノリン誘導体 Pending JP2016519091A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361802891P 2013-03-18 2013-03-18
US61/802,891 2013-03-18
PCT/IL2014/050273 WO2014147611A1 (en) 2013-03-18 2014-03-13 Quinolines derivatives as novel anticancer agents

Publications (2)

Publication Number Publication Date
JP2016519091A JP2016519091A (ja) 2016-06-30
JP2016519091A5 true JP2016519091A5 (https=) 2017-03-09

Family

ID=51579387

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016503776A Pending JP2016519091A (ja) 2013-03-18 2014-03-13 新規抗がん剤としてのキノリン誘導体

Country Status (13)

Country Link
US (1) US10179770B2 (https=)
EP (1) EP2976333B1 (https=)
JP (1) JP2016519091A (https=)
KR (1) KR20150132192A (https=)
CN (1) CN105102442B (https=)
AU (1) AU2014233757B2 (https=)
BR (1) BR112015023948A2 (https=)
CA (1) CA2902734A1 (https=)
MX (1) MX2015013396A (https=)
NZ (1) NZ710854A (https=)
SG (1) SG11201506385WA (https=)
WO (1) WO2014147611A1 (https=)
ZA (1) ZA201506880B (https=)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2956138B1 (en) 2013-02-15 2022-06-22 Kala Pharmaceuticals, Inc. Therapeutic compounds and uses thereof
US9688688B2 (en) 2013-02-20 2017-06-27 Kala Pharmaceuticals, Inc. Crystalline forms of 4-((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxyquinazolin-7-yl)oxy)-1-(2-oxa-7-azaspiro[3.5]nonan-7-yl)butan-1-one and uses thereof
MX368903B (es) 2013-02-20 2019-10-21 Kala Pharmaceuticals Inc Compuestos terapéuticos y sus usos en el tratamiento de enfermedades proliferativas.
RS60093B1 (sr) 2013-09-16 2020-05-29 Astrazeneca Ab Terapeutske polimerne nanočestice i postupci njihove pripreme i primene
US9890173B2 (en) 2013-11-01 2018-02-13 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
US9458169B2 (en) 2013-11-01 2016-10-04 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
JP2016538306A (ja) * 2013-11-27 2016-12-08 アメリカ合衆国 複素環化合物及びその使用方法
US10626094B2 (en) 2014-10-14 2020-04-21 Sanford Burnham Prebys Medical Discovery Institute Inhibitors of low molecular weight protein tyrosine phosphatase and uses thereof
TR201900148T4 (tr) * 2014-10-31 2019-02-21 Genoscience Pharma Sas Kansere karşı yeni maddeler olarak sübstitüe edilmiş 2,4 diamino-kinolin.
BR112018008630A2 (pt) 2015-11-06 2018-10-30 Neurocrine Biosciences Inc derivados de n-[2-(1-benzilpiperidin-4-il)etil]-4-(pirazin-2-il)-piperazina-1-carboxamida, seus usos, composição farmacêutica
EA039638B1 (ru) * 2016-01-06 2022-02-21 Нейрокрин Байосайенсиз, Инк. Антагонисты мускаринового рецептора 4 и способы их применения
US20170240535A1 (en) * 2016-02-01 2017-08-24 Regenacy Pharmaceuticals, Llc Hdac1/2 inhibitors for the treatment of neurodegenerative and/or cognitive disorders
DK3452465T3 (da) * 2016-05-04 2021-02-08 Genoscience Pharma Substituerede 2,4-diaminoquinolinderivater til anvendelse til behandling af proliferative sygdomme
CN106008339B (zh) * 2016-06-08 2018-09-07 上海准视生物科技有限公司 一种放射性c-met靶向亲和小分子化合物及其应用
US10336767B2 (en) 2016-09-08 2019-07-02 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
AU2017324713B2 (en) 2016-09-08 2020-08-13 KALA BIO, Inc. Crystalline forms of therapeutic compounds and uses thereof
EP3509423A4 (en) 2016-09-08 2020-05-13 Kala Pharmaceuticals, Inc. CRYSTALLINE FORMS OF THERAPEUTIC COMPOUNDS AND USES THEREOF
EP4275759B1 (en) * 2016-09-26 2025-12-24 Dana-Farber Cancer Institute, Inc. Quinoline derivatives as chromobox (cbx) protein inhibitors for treating cancer
CN106619633B (zh) * 2016-12-16 2019-05-31 江苏大学 Fpthq在制备治疗卵巢癌的药物中的应用
CN106619634B (zh) * 2016-12-16 2019-05-31 江苏大学 化合物4-bpt在制备治疗卵巢癌药物中的应用
CN106727559B (zh) * 2016-12-16 2019-05-31 江苏大学 7-mdt在制备治疗卵巢癌的药物中的应用
ES2928773T3 (es) 2017-01-17 2022-11-22 Heparegenix Gmbh Inhibidores de proteína cinasas para fomentar la regeneración hepática o reducir o prevenir la muerte de hepatocitos
WO2018204176A1 (en) 2017-05-01 2018-11-08 Sanford Burnham Prebys Medical Discovery Institute Inhibitors of low molecular weight protein tyrosine phosphatase (lmptp) and uses thereof
US11065265B2 (en) 2018-05-18 2021-07-20 Spes Pharmaceuticals Inc. Compositions of fosaprepitant and methods of preparation
CN110437149B (zh) * 2019-08-20 2021-01-29 大连民族大学 抗肿瘤活性的天然萘基异喹啉类化合物及其组合物、应用
US20220388962A1 (en) * 2019-08-22 2022-12-08 Biohaven Therapeutics Ltd. Molecules that bind to tdp-43 for the treatment of amyotrophic lateral sclerosis and related disorders
US12486250B2 (en) 2019-12-06 2025-12-02 Neurocrine Biosciences, Inc. Muscarinic receptor 4 antagonists and methods of use
CN115108977B (zh) * 2021-03-19 2024-11-29 南京正大天晴制药有限公司 一种瑞戈非尼的制备方法
CN114533733A (zh) * 2021-12-31 2022-05-27 北京鑫开元医药科技有限公司 一种异喹啉-1,3-二胺类似物药物制剂及其制备方法
CN113999206B (zh) * 2021-12-31 2022-04-12 北京鑫开元医药科技有限公司 异喹啉-1,3-二胺类似物、制备方法、药物组合物及其应用
CN115745889B (zh) * 2022-12-07 2025-03-14 中国人民解放军空军军医大学 一类含有2-芳基-4-取代喹啉结构的化合物及其制备方法与应用
CN116726007A (zh) * 2023-05-11 2023-09-12 中国人民解放军总医院第二医学中心 来曲唑在制备治疗淋巴瘤的药物中的用途
US20250145573A1 (en) * 2023-11-03 2025-05-08 Ckp Therapeutics, Inc. Composition for preventing, alleviating or treating cancer
CN118164954B (zh) * 2024-03-13 2024-09-27 江苏蒙博生物工程科技有限公司 一种基于10-羟基苯并[h]喹啉荧光母核的荧光探针、制备方法与应用
WO2026026894A1 (zh) * 2024-08-01 2026-02-05 浙江奥翔药业股份有限公司 一种角鲨胺关键中间体的制备方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1886781A (en) * 1932-11-08 Multiplying mechanism for calculating machines
US1886481A (en) 1927-11-07 1932-11-08 Soc Of Chemical Ind Unilaterally acylated diamines and process of making same
US4560692A (en) * 1984-07-18 1985-12-24 Hoffmann-La Roche Inc. 4-Piperidino-2-phenylquinolines
JPH02129169A (ja) * 1988-11-08 1990-05-17 Ube Ind Ltd キノリン化合物およびその医薬用途
US6172084B1 (en) 1997-06-19 2001-01-09 Sepracor, Inc. Quinoline-indole antimicrobial agents, uses and compositions related thereto
US6103905A (en) * 1997-06-19 2000-08-15 Sepracor, Inc. Quinoline-indole antimicrobial agents, uses and compositions related thereto
EP1377554A1 (en) * 1999-06-16 2004-01-07 University Of Iowa Research Foundation Antagonism of immunostimulatory cpg-oligonucleotides by 4-aminoquinolines and other weak bases
SE9902987D0 (sv) * 1999-08-24 1999-08-24 Astra Pharma Prod Novel compounds
CN1642599A (zh) * 2002-02-27 2005-07-20 辉瑞产品公司 Acc抑制剂
EP1694686A1 (en) * 2003-12-19 2006-08-30 Takeda San Diego, Inc. Kinase inhibitors
EP1856099A2 (en) * 2005-03-03 2007-11-21 Sirtris Pharmaceuticals, Inc. Acridine and quinoline derivatives as sirtuin modulators
US20100150844A1 (en) * 2006-07-28 2010-06-17 The Johns Hopkins University Use of 8-quinolinol and its analogs to target cancer stem cells
WO2011130677A1 (en) 2010-04-16 2011-10-20 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Inhibitors of cancer stem cells

Similar Documents

Publication Publication Date Title
JP2016519091A5 (https=)
US11753397B2 (en) Cereblon binders for the degradation of ikaros
EP2976333B1 (en) Quinolines derivatives as novel anticancer agents
US11639335B2 (en) Asymmetric bisaminoquinolines and bisaminoquinolines with varied linkers as autophagy inhibitors for cancer and other therapy
JP2017538673A5 (https=)
EP4303583A2 (en) Methods of treating disorders using csf1r inhibitors cross-reference to related applications
CA3174245A1 (en) Therapeutics for the degradation of mutant braf
IL319363A (en) Cervalon ligands and bifunctional compounds containing them
WO2008076278A4 (en) Methods of cancer treatment with igf1r inhibitors
KR102846292B1 (ko) Etbr 활성화와 관련된 암을 치료하기 위한 중수소화 화합물, 조성물, 및 방법
US10512651B2 (en) Inhibition of MK2 in the treatment of cancer
KR20240019099A (ko) 뇌 또는 cns로의 암 전이를 치료하기 위한 egfr 분해제
CA3147639A1 (en) Treatment of urothelial and kidney cancers by use of endothelin b receptor antagonists
JP2025525917A (ja) Retタンパク質を調節するための化合物
WO2021178789A1 (en) Methods of using rebastinib in the treatment of different cancerous disorders
CA3218436A1 (en) Ripretinib for treating melanoma
TW202542141A (zh) 雙重raf及微管蛋白抑制劑及其使用方法
WO2025129116A1 (en) Compounds for the targeted degradation of smarca2
EA046650B1 (ru) Дейтерированные соединения, композиции и способы для лечения рака, связанного с активацией etbr
TW202515860A (zh) 雙重raf及微管蛋白抑制劑及其使用方法